Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Moon

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 22, 2022
Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 PandemicSasha Deutsch-Link, Yue Jiang, Anne F Peery, et al.
Hepatology Communications|September 12, 2021
Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing InvestigationAndrew M Moon, Brenda Curtis, Pranoti Mandrekar, et al.
Clinical Transplantation|February 9, 2022
Changing opportunities for liver transplant for patients with hepatocellular carcinomaAlex Zendel, Randall Watkins, Andrew M Moon, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2020
Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' replyAndrew M Moon, Yue Jiang, Shari S Rogal, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosisAndrew M Moon, Yue Jiang, Shari S Rogal, et al.
Nature Reviews. Gastroenterology & Hepatology|March 11, 2021
COVID-19 and liver disease: mechanistic and clinical perspectivesThomas Marjot, Gwilym J Webb, Alfred S Barritt, et al.
The American Journal of Gastroenterology|December 17, 2025
Enhancing Patient Empowerment through Artificial Intelligence in Liver CancerDee Lee, Zorana Maravic, Andrew M Moon, et al.
Digestive Diseases and Sciences|July 13, 2020
Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis CJihane N Benhammou, Andrew M Moon, Joseph R Pisegna, et al.
The American Journal of Gastroenterology|February 2, 2023
Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic EncephalopathyAndrew M Moon, Hannah P Kim, Yue Jiang, et al.
Alimentary Pharmacology & Therapeutics|November 13, 2023
Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradicationPhilip Vutien, Nicole J Kim, Andrew M Moon, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 22, 2022
Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 PandemicSasha Deutsch-Link, Yue Jiang, Anne F Peery, et al.
Hepatology Communications|September 12, 2021
Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing InvestigationAndrew M Moon, Brenda Curtis, Pranoti Mandrekar, et al.
Clinical Transplantation|February 9, 2022
Changing opportunities for liver transplant for patients with hepatocellular carcinomaAlex Zendel, Randall Watkins, Andrew M Moon, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2020
Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' replyAndrew M Moon, Yue Jiang, Shari S Rogal, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosisAndrew M Moon, Yue Jiang, Shari S Rogal, et al.
Nature Reviews. Gastroenterology & Hepatology|March 11, 2021
COVID-19 and liver disease: mechanistic and clinical perspectivesThomas Marjot, Gwilym J Webb, Alfred S Barritt, et al.
The American Journal of Gastroenterology|December 17, 2025
Enhancing Patient Empowerment through Artificial Intelligence in Liver CancerDee Lee, Zorana Maravic, Andrew M Moon, et al.
Digestive Diseases and Sciences|July 13, 2020
Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis CJihane N Benhammou, Andrew M Moon, Joseph R Pisegna, et al.
The American Journal of Gastroenterology|February 2, 2023
Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic EncephalopathyAndrew M Moon, Hannah P Kim, Yue Jiang, et al.
Alimentary Pharmacology & Therapeutics|November 13, 2023
Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradicationPhilip Vutien, Nicole J Kim, Andrew M Moon, et al.
Pageof 11